Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 18, Issue 6

November-December 2021

In this Issue

Clinical Trials Corner
Diffusion
Features
Headlines from Washington
Image Challenge
In Memoriam
Op-Ed
President's Column

Clinical Trials Corner

Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma

Binod Dhakal, MD,Saad Usmani, MD, MBA, FACP

View Articletitled, Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma

Diffusion

Belumosudil: A Rising Star for the Management of Chronic Graft-Versus-Host Disease and the First FDA-Approved ROCK2 Inhibitor

Tony J. Kurian, MD,Frederick Locke, MD

View Articletitled, Belumosudil: A Rising Star for the Management of Chronic Graft-Versus-Host Disease and the First FDA-Approved ROCK2 Inhibitor

Older Patients With High-Risk MDS Benefit From Allogeneic Stem Cell Transplantation

Michael J. Hochman, MD,Amy DeZern, MD, MHS

View Articletitled, Older Patients With High-Risk MDS Benefit From Allogeneic Stem Cell Transplantation

Weighing the Risk and Benefits of Direct Oral Anticoagulants in Morbidly Obese Patients: New Data and Guidance

Damon E. Houghton, MD, MSc,Waldemar Wysokinski, MD, PhD

View Articletitled, Weighing the Risk and Benefits of Direct Oral Anticoagulants in Morbidly Obese Patients: New Data and Guidance

Don’t Let Perfect Be the Enemy of Good: Why Point-of-Care Testing in Resource-Poor Countries Is Feasible and Reasonable

Ifeyinwa (Ify) Osunkwo, MD, MPH

View Articletitled, Don’t Let Perfect Be the Enemy of Good: Why Point-of-Care Testing in Resource-Poor Countries Is Feasible and Reasonable

Ironing Things Out: What Ferritin Level Should Be Used to Diagnose Iron Deficiency?

Eric Tseng, MD, MScCH, FRCPC

View Articletitled, Ironing Things Out: What Ferritin Level Should Be Used to Diagnose Iron Deficiency?

Major Advances in Hairy Cell Leukemia

Brad Kahl, MD

View Articletitled, Major Advances in Hairy Cell Leukemia

Phat Mass and Ph-like ALL: A Link Between Obesity and CRLF2 Rearrangements?

Sarah K. Tasian, MD

View Articletitled, Phat Mass and Ph-like ALL: A Link Between Obesity and <em>CRLF2</em> Rearrangements?

Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers

Michael J. Lane, BSc, MBBS, FRACP, FRCPA,Steven Lane, MBBS, PhD, FRACP, FRCPA

View Articletitled, Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers

Separating Innocuous “CHIP” Mutations From Ominous “CHOP” Mutations in Patients With Treated AML in Remission

Megan J. Fitzpatrick, MD,Robert P. Hasserjian, MD

View Articletitled, Separating Innocuous “CHIP” Mutations From Ominous “CHOP” Mutations in Patients With Treated AML in Remission

TaLLy-ing Up Prognostic Features for T-Lymphoblastic Lymphoma

Kim Seymour, MD,Kristen M. O’Dwyer, MD

View Articletitled, TaLLy-ing Up Prognostic Features for T-Lymphoblastic Lymphoma

Clonal Hematopoiesis: An Abrupt and Inevitable Consequence of Aging?

Adam Mead, MD, PhD

View Articletitled, Clonal Hematopoiesis: An Abrupt and Inevitable Consequence of Aging?

Features

Reflections on the Reticulocyte Count: The Importance of a “Complete” Blood Count

Marshall A. Lichtman, MD

View Articletitled, Reflections on the Reticulocyte Count: The Importance of a “Complete” Blood Count

Headlines from Washington

ASH Advocates Count Sickle Cell Legislative Achievements in 2021

ASH Staff

View Articletitled, ASH Advocates Count Sickle Cell Legislative Achievements in 2021

Image Challenge

Quality Over Quantity: A Case of Too Many

May Chien, MD,Clara Lo, MD,Bertil Glader, MD

View Articletitled, Quality Over Quantity: A Case of Too Many

In Memoriam

A Gentleman and a Scholar: Elihu H. Estey, MD (1946 –2021)

Mary-Elizabeth M. Percival, MD, MS,Roland B. Walter, MD, PhD, MS,Anna B. Halpern, MD,Frederick R. Appelbaum, MD,Janis L. Abkowitz, MD

View Articletitled, A Gentleman and a Scholar: Elihu H. Estey, MD (1946 –2021)

Op-Ed

The ASH Subcommittee on Clinical Trials: A Focus on Improving Clinical Trial Options for Hematology Patients

Laura C. Michaelis, MD

View Articletitled, The ASH Subcommittee on Clinical Trials: A Focus on Improving Clinical Trial Options for Hematology Patients

President's Column

No Stone Left Unturned

Martin S. Tallman, MD

View Articletitled, No Stone Left Unturned

Cover Image

Cover Image

All Issues

Advertisement intended for health care professionals

Email alerts

Latest Issue Alert

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read

Vitamin A to Keep GVHD Away: Single Oral High-Dose Vitamin A Before Bone Marrow Transplant Reduces Graft-Versus-Host Disease in Pediatric and Young Adult Patients

Trainee Corner
A Career in Academia: Should I Stay or Should I Go?

Then and Now
Treatment for Acute Leukemia in Older Adults: Two Decades of Remarkable Progress

Does Sustained Monocytosis Always Mean CMML? A Case of Ras-Associated Autoimmune Leukoproliferative Disorder

ASH and Federal Officials Hold Town Hall on Sickle Cell Disease

Advertisement intended for health care professionals

Table of Contents

Clinical Trials Corner

Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma

Diffusion

Belumosudil: A Rising Star for the Management of Chronic Graft-Versus-Host Disease and the First FDA-Approved ROCK2 Inhibitor

Older Patients With High-Risk MDS Benefit From Allogeneic Stem Cell Transplantation

Weighing the Risk and Benefits of Direct Oral Anticoagulants in Morbidly Obese Patients: New Data and Guidance

Don’t Let Perfect Be the Enemy of Good: Why Point-of-Care Testing in Resource-Poor Countries Is Feasible and Reasonable

Ironing Things Out: What Ferritin Level Should Be Used to Diagnose Iron Deficiency?

Major Advances in Hairy Cell Leukemia

Phat Mass and Ph-like ALL: A Link Between Obesity and CRLF2 Rearrangements?

Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers

Separating Innocuous “CHIP” Mutations From Ominous “CHOP” Mutations in Patients With Treated AML in Remission

TaLLy-ing Up Prognostic Features for T-Lymphoblastic Lymphoma

Clonal Hematopoiesis: An Abrupt and Inevitable Consequence of Aging?

Features

Reflections on the Reticulocyte Count: The Importance of a “Complete” Blood Count

Headlines from Washington

ASH Advocates Count Sickle Cell Legislative Achievements in 2021

Image Challenge

Quality Over Quantity: A Case of Too Many

In Memoriam

A Gentleman and a Scholar: Elihu H. Estey, MD (1946 –2021)

Op-Ed

The ASH Subcommittee on Clinical Trials: A Focus on Improving Clinical Trial Options for Hematology Patients

President's Column

No Stone Left Unturned

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Clinical Trials Corner

Diffusion

Features

Headlines from Washington

Image Challenge

In Memoriam

Op-Ed

President's Column

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only